Saad Usmani

Feb 17, 2015

Saad Usmani has been appointed Acting CMO of SkylineDx, where he will lead the overall clinical vision of the Dutch cancer molecular diagnostics firm. Usmani is currently the director of clinical research (hematologic malignancies) and director of plasma cell disorders at Carolinas HealthCare System's Levine Cancer Institute. He previously was director of developmental therapeutics at the University of Arkansas.

Breaking News

Foresight Diagnostics Launches Lymphoma Personalized Treatment Clinical Trial
VA Offering No-Cost PGx Testing Through End of 2025
Baylor Receives $3.5M From NHGRI to Study Newborn Genetic Telehealth Services in Texas
Investigators Urge Additional Screening to Catch Maternal Cancer From Nonreportable NIPT Results
GeneDx Launches Program to Boost Access to Exome Testing for Pediatric Epilepsy Patients

Saad Usmani

Foresight Diagnostics Launches Lymphoma Personalized Treatment Clinical Trial

VA Offering No-Cost PGx Testing Through End of 2025

Baylor Receives $3.5M From NHGRI to Study Newborn Genetic Telehealth Services in Texas

Investigators Urge Additional Screening to Catch Maternal Cancer From Nonreportable NIPT Results

GeneDx Launches Program to Boost Access to Exome Testing for Pediatric Epilepsy Patients